Edwards Lifesciences Corp (EW) released its first quarter results on Wednesday, April 21, 2021. The company reported net earnings of $0.54 per share for the first quarter ending March 31, 2021. Earnings for this past quarter were up 10 percent compared to the same period a year ago.
Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.
Edwards Lifesciences's revenue decreased 0 percent over the past trailing twelve-month period versus the previous twelve-month period. Gross margins decreased to 75.97% for the first quarter compared to the same period in the previous year, and operating margins decreased to 31.68% over the same period. Net earnings for past trailing twelve months were $851.0 million, down 23% from the prior year.
Moving on to the balance sheet, Edwards Lifesciences’s cash levels jumped 77% for the third quarter over the same period last year. Overall liquidity of the balance sheet, as measured by the current ratio, increased 14.4% this past year. The current ratio for Edwards Lifesciences now stands at 3.84. The company decreased shares outstanding by 0.48%.
Shares of EW are currently trading around $95.24. In terms of valuation, the stock is trading at a trailing twelve-month price to earnings ratio of 70.62 and price to book ratio of 12.91.